度他雄胺在医保范围内吗？

On October 9, 2002, dutasteride was approved by the U.S. Food and Drug Administration for the treatment of prostate enlargement. On June 19, 2008, GlaxoSmithKline announced that the U.S. FDA had approved the combination of dutasteride and tamsulosin for the treatment of prostatic hyperplasia. It is the first and only dual 5-alpha reductase inhibitor for the treatment of prostatic hyperplasia, which can improve urinary symptoms and reduce the risk of acute urinary retention episodes and related prostate surgery. Tamsulosin is an α-receptor blocker that can improve the symptoms of prostatic hyperplasia.

There are two types of 5α reductase in the human body, type I and type II. Type II is mainly found in the prostate, and type I is mainly distributed in the liver and skin. 5α reductase is an important reason for the continuous progression of benign prostatic hyperplasia. It can promote the conversion of testosterone in the patient's prostate to the more active dihydrotestosterone, thus leading to the proliferation of prostate cells and prostate hypertrophy. Therefore, the key to treating benign prostatic hyperplasia lies in inhibiting 5α-reductase. Dutasteride can inhibit both type I and type II 5α reductase. Through this 'dual inhibition' mechanism, dutasteride can quickly and continuously reduce prostate volume, significantly improve lower urinary tract symptoms, reduce acute urinary retention and related prostate surgery risks, and provide long-lasting benefits to patients, especially the majority of patients with moderate and severe benign prostatic hyperplasia.

Is dutasteride covered by medical insurance?

Ningxia has entered Class B medical insurance. Since the medical insurance directory system is different in each province, patients need to go to the medical insurance institution to inquire whether dutasteride is a medically insured drug.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: